Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus Disease-19 infection
Gorial et al.
, Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus..
, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103593
RCT with 80 colchicine and 80 control patients, showing improved recovery with treatment. SOC included vitamin C, vitamin D, and zinc.
risk of death, 66.7% lower, RR 0.33, p = 0.62, treatment 1 of 80 (1.2%), control 3 of 80 (3.8%), NNT 40.
risk of no recovery, 62.8% lower, HR 0.37, p < 0.001, treatment 80, control 80, inverted to make HR<1 favor treatment, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gorial et al., 12 Apr 2022, Randomized Controlled Trial, Iraq, peer-reviewed, 6 authors, dosage 1mg days 1-7, 0.5mg days 8-15.
Abstract: Journal Pre-proof
Randomized controlled trial of colchicine add on to the standard therapy in moderate
and severe corona virus Disease-19 infection
Faiq I. Gorial, Mohammed Fauzi Maulood, Ahmed S. Abdulamir, Ahmed Sameer
Alnuaimi, Manal K. abdulrrazaq, Fadil Agla Bonyan
To appear in:
Annals of Medicine and Surgery
Received Date: 18 February 2022
1 April 2022
Accepted Date: 2 April 2022
Please cite this article as: Gorial FI, Maulood MF, Abdulamir AS, Alnuaimi AS, abdulrrazaq MK, Bonyan
FA, Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe
corona virus Disease-19 infection, Annals of Medicine and Surgery (2022), doi: https://doi.org/10.1016/
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2022 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.
A Randomized Controlled Trial of Colchicine add on to the Standard
Therapy in Moderate and Severe Corona Virus Disease-19 Infection
Faiq I. Gorial 1, Mohammed Fauzi Maulood2 , , Ahmed S. Abdulamir 3 , Ahmed
Sameer Alnuaimi 4, Manal K. abdulrrazaq 5, Fadil Agla Bonyan 6
1, 5 College of Medicine, University of Baghdad, Bab Al-Muadham, Baghdad, Iraq
2 Alkarkh Hospital, Alatefiya, Baghdad, Iraq
3 College of Medicine, Alnahrain University, Alkadymia, Baghdad, Iraq
4 Primary Health Care Corporation, Department Of Clinical Research, Aldoha, Qatar
6 Emergency physician, Director of EMS of Iraq, Emergency medical department, Baghdad
Corresponding author email: firstname.lastname@example.org
Running title: Colchicine as Add-on Therapy to the Standard of Care Measures in COVID-19
Table 1: Baseline characteristics of the study groups.
on) + moderate Control + Severe
on) + Severe
Age group (years)
Ischemic Heart Disease
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.